Valuation: Pegasus Mercantile Inc.

Market Cap 735K 531K 455K 427K 390K 50.65M 743K 5.03M 1.96M 25.55M 1.99M 1.95M 84.62M P/E 2024
-2.5x
P/E 2025 -1.67x
Enterprise Value 825K 596K 511K 478K 437K 56.81M 833K 5.64M 2.2M 28.66M 2.24M 2.19M 94.91M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
78.18%
Yield 2024 *
-
Yield 2025 -
Current month+37.50%
1 month+57.14%
6 months-31.25%
Current year+10.00%
1 week 0.06
Extreme 0.055
0.06
1 month 0.04
Extreme 0.04
0.06
Current year 0.03
Extreme 0.03
0.15
1 year 0
Extreme 0.005
0.15
3 years 0
Extreme 0.005
0.58
5 years 0
Extreme 0.005
2.5
10 years 0
Extreme 0.005
14
Manager TitleAgeSince
Chief Executive Officer - 2017-11-29
Director of Finance/CFO 72 2022-02-28
Corporate Secretary - -
Director TitleAgeSince
Director/Board Member - 2017-11-29
Director/Board Member 72 2019-04-09
Director/Board Member - 2024-11-25
Date Insider Type Main position Quantity % Market Cap.
1/31/25 Tax

Chief Executive Officer

55,000 -
1/31/25 Tax

Chief Financial Officer

20,000 -
1/31/25 Tax

Chief Financial Officer

40,000 -
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-42.11%-78.00% 531K
+0.34%+1.93%+3.48%+74.07% 182B
+1.32%+2.12%+35.66%+99.23% 165B
+0.93%-0.17%+58.70%+274.23% 111B
+0.21%-0.67%-2.95%+97.68% 93.88B
+0.26%+1.33%-12.86%+60.68% 83.79B
+1.06%+0.56%+67.91%+185.64% 53B
-0.16%-0.33%+9.53%+67.68% 49.49B
-1.39%+1.39%-30.24%+45.15% 39.67B
+0.09%-1.97%+43.04%+150.19% 34.18B
Average +0.26%+0.50%+13.02%+97.65% 81.21B
Weighted average by Cap. +0.51%+0.72%+19.72%+116.57%

Financials

2024 2025
Net sales - -
Net income -546K -394K -338K -317K -289K -37.61M -551K -3.74M -1.45M -18.97M -1.48M -1.45M -62.83M -381K -275K -236K -221K -202K -26.25M -385K -2.61M -1.02M -13.24M -1.03M -1.01M -43.86M
Net Debt 76.82K 55.5K 47.56K 44.56K 40.71K 5.29M 77.58K 526K 205K 2.67M 208K 204K 8.84M 89.43K 64.61K 55.37K 51.88K 47.39K 6.16M 90.32K 612K 238K 3.11M 243K 237K 10.29M
Logo Pegasus Mercantile Inc.
Pegasus Mercantile Inc. is a Canada-based prospect generator that provides companies with technology, financial, operational, and management assistance in the market for global wellness products and novel consumer goods and services. The Company is focused on hemp, cannabidiol (CBD), related, functional mushrooms, psilocybin plus other psychedelics, helping companies create sustainable products that elevate their personal health and wellbeing. It is focused on the specific areas of pain, depression and mental illness. By investing in pioneering techniques, such as micro-dosing using organic compounds and synthetic molecules. It is transforming the treatment of chronic pain, psychiatric ailments and depression by pioneering trials of fixed-dose drugs, combining psilocybin, ketamine, and MDMA, embracing the endless possibilities of micro-dosing. It has 100% interest in Shanti Therapeutics Pty Ltd. (Shanti), which is focused on psychedelic MDMA-based drug development research.
Employees
-
Date Price Change Volume
26-08-21 $0.0550 0.00% 20,000
  1. Stock Market
  2. Stocks
  3. LOAN.X Stock